能倍乐 思力华噻托溴铵的效果好不好

Slivar tiotropium bromide is suitable for the maintenance treatment of chronic obstructive pulmonary disease (COPD, including chronic bronchitis and emphysema) and related dyspnea. It can improve the quality of life of COPD patients and reduce acute exacerbations of COPD. Use by inhalation. Bottles containing tiotropium bromide may only be used by inserting the Respimat inhalation device and inhaling it through the Respimat inhalation device. The recommended dose for adults is 2 puffs taken once daily via the Respimat inhaler device at the same time. Patients should not overdose.

Elderly patients do not need to change their dosage. COPD rarely occurs in children, and the safety of the medication is unknown. Patients with renal insufficiency can use it at the recommended dosage. However, for patients with moderate to severe renal insufficiency (creatinine clearance ≤50ml/minute), the use of this product should be closely monitored. Patients with hepatic impairment do not require medication adjustments.

Effects of Respimat, Slava, Tiotropium Bromide:

In a research trial, 298 patients with chronic obstructive pulmonary disease were included and randomly divided into an observation group (149 cases) and a control group (149 cases). The observation group was treated with tiotropium bromide for 3 months, and the control group was treated with aminophylline for 3 months. The results showed that the lung function increase index of patients treated with Respimat, Slava and Tiotropium was significantly better than that of the control group, and the difference was statistically significant. In terms of the incidence rate of adverse reactions, the incidence rate in the Respimat, Slava, Tiotropium bromide treatment group was 3.3%, and that in the control group was 10.7%. The difference between the two groups was statistically significant. Patients' treatment with Respimat, Slava, and Tiotropium bromide can effectively improve lung function indicators with significant results.

Recommended related hot articles: /newsDetail/85150.html